by Elena Iemma | Jan 12, 2026 | Blog, News
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Aug 19, 2025 | Blog
The Tregs as Medicine Symposium September 26, 2025 | The Westin Hotel, Meguro Tokyo The Tregs as Medicine: Tolerance and InTolerance Symposium will bring together leading scientists and clinicians to examine how regulatory T cells (Tregs) and tolerance...
by Elena Iemma | Jul 17, 2025 | Blog
Tregs, Epitopes, and the Future of Immune Tolerance Making Sense of Natural Constraint Contrary to popular (immunologist) belief, there’s nothing ‘non-specific’ about Tregs! Otherwise why would they carry TCR (T cell receptors) that bind to their...
by Elena Iemma | May 28, 2025 | News
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO PROVIDENCE, R.I., May 28, 2025 /PRNewswire/ — EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the...
by Elena Iemma | Apr 30, 2025 | Events
The 11th annual Amsterdam Immunogenicity & Tolerance Seminar November 7, 2025 | 8:30 am – 4:00 pm with reception to follow | The Hilton Apollolaan Hotel Registration is now closed About the Amsterdam Immunogenicity & Tolerance Seminar: Now in its 11th...
